Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly Doc. That seems the most reasonable answer.
Sorry I should have asked if you knew where people were getting the buzz light year information from the filing. To me it looks like it’s mostly about making sure management gets paid.
That doesn't belong in the proxy.
Partner butter and Jama
Peanut butter and JaMAA
Peanut butter and JaMIA
Meant to include the SPORE grant link to confirm the CSF-1Ri / PLX3397 trial with a PD-1 mAb blockade drug that could be BMY's drug given the previous trial that had been scheduled AND Dr. Liau's discussion of the CSF-1Ri related possible trial in her clinical discussion in the previous post, at the very bottom, previously highlighted by ATL.
Did it again, did not include the link:
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm
Genuinely confused by the post. All is see is electing board members, confirming exec comp and asking for more shares.
Nothing about a single catalyst that moves this forward prior to the meeting
Interesting perspective- let’s play the other side! Many longs, including yourself put a value on TLD, JA and SNO! Read that guaranteed $4-5 on those three things! How did that turn out?
Linda is out of ammo at the moment! Now back to speculation and hope!
I'm not at all optimistic about tomorrow or next week and expect a beating this week if there is no further news coming from mgt at the open tomorrow or during the week. Given mgts penchant for silence I have no confidence we'll see any such thing. I expect more "buying opportunities" are in the offing.
is there a different section of the filing I should be looking at? From what I see it’s the following:
We are holding the Annual Meeting for the following purposes:
1.
To elect two members to our Board of Directors to serve as Class III Directors for a term of three years;
?
2.
To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
?
3.
To ratify the same stock option awards that were made to the Company’s executive officers in 2020 and for which the stockholders already voted in favor in an advisory vote by stockholders at last year’s 2021 Annual Meeting;
?
4.
To approve, on an advisory basis, the Company’s executive compensation;
?
5.
To approve the previously reported option awards made in 2020 to the independent directors on the Company’s Board of Directors;
?
6.
To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase our authorized shares of common stock, by 500,000,000 from 1,200,000,000 to 1,700,000,000, par value $0.001 per share (the “Common Stock”); and
?
7.
To act upon such other matters as may properly come before the meeting or any adjournments or postponements thereof.
?
I hope management will take a peek here and see the mix opinion of shareholders about the AS increase. I’m positive that without news or plan in the upcoming week, management won’t get all the yes.
Really! Who promised? The company? Awesome, please link the article to that! Specific to pre-ASM, not the PR about intention to someday seek approval!
Anticipation? Agreed…pretty much this clown show of management relies on! Anticipation and hope…
Again I hope y’all are right but reading the filing on Friday def left a nervousness on my part. If you are willing… do you mind expanding on any details around where you think this is heading and why?
Thanks, horse
Your reply makes perfect sense.
Yes, licensing the IP would be like that except in a pure licensing deal the IP owner receives the compensation without having to make anything.
The revenue from sales of murcidencel is separate in my understanding.
Sure but is your opinion based on something in the asm proxy or based on some hangover level mathematics that is not really verifiable until the asm? Reading the company main objectives for the asm it’s pretty clear imo that management getting paid(sorry edit here.. getting paid and not sued) is a very high priority , hopefully they care as much about us little guys too.
I hope you’re right about the so tomorrow and it launches to the moon but I am def a bit nervous and I would guess a few others are too.
Hank, I agree, reality is beginning to settle in for where this is headed. Next week will certainly be interesting.
Jester, sorry about your friend. The disease is awful. The facts tell me we now have science / tools necessary to improve outcomes. Now we need the financial tools. My experience leads me to believe voting with management in this case is the best chance to create the financial tools needed to begin the next processes and keep this amazing ball in the air for now. A wise person once told me to love with your heart and do business and make money with your head. It seems like you are on that path. GLTA
Thank you for your message as it helps in not beating myself up as much. While the afflicted bears the heaviest toll by far, as caregivers and trusted children we also accumulate stresses and regrets, but such is life for too many.
LP and LL and LG and others know the toll full well and they were capable of doing something and carrying it out!
I’m not going to make their challenges greater at the dawn of this new era after enduring a long darkness with the proponents of the darkness still trying to drag them down from reaching success.
thermo
Re: None
Sunday, November 27, 2022 6:27:26 PM
Post#
539515
Should be an interesting week.
I beg to differ. The setting of the ASM date and the promise and anticipation of more good news over the next 33 days leading up to the ASM should IMO have a very positive effect on the share price. The shorts are getting to understand that this is for real and not going away. They are going to have to learn to live with this reality. They had it good for a while, but the easy money is gone for the shorts. We should also have news from the UK any day as well that will be a major push for the longs and of course the always possible partnership announcement. I do not see this going down as a result of the ASM, but of course the manipulators may go for one more try, but I doubt they will have any serious success again like they did on May 10 (which btw, did not succeed to kill off NWBO).
It’s a single source article for the controversy though? It does seem lazy in this case to me since they just skimmed the stat article and used it as the negative side of the article they focused on. I’m was not a literary major but I did take a few classes on analyzing and evaluating persuasive arguments.
Horse,
Forgot adding the keyword: GO NWBO.
Since you mentioned about licensing to BPs, I was curious if
this is something like the ARM business model which develops intellectual property in chip developing and licenses to its partners.
Thanks.
No worry there. I am confident the regulators will do the right procedures,
Go NWBO.
Naked Shorting is a different Beast entirely. Naked Shorting drives stocks to the moon when the available demand exceeds available supply in short time frames. Thee day Settlements gives Da Crooks time but the cost incurred is vast.
I think you're wrong. Companies vote to honor their contractual obligations. Right now their obligations are to employees and directors. Those are commercial and civil law issues and those persons are not going to bring suit because they know the company is going to honor those rights and shareholders are likely going to do the correct thing, rather than the cut off their noses to spite themselves thing.
I won't claim to have calculated first hand, but shorts argue one thing and then another. One argument previously, was that they really had some absurd level of shares outstanding because their warrants were out ahead of their outstanding shares, and that that was one reason for some agreeing to delay their exercise.
I think some early estimates of that were outlandishly large, but the fact is, they need more shares to utilize fully their preferred c class and warrants, to some degree potentially. I'm not here to educate you on it, you need to do your own due diligence.
However, there are obvious reasons why a company needs shares to move from development stage to an operating company and people who vote against reasonable authorized shares to finance going forward, I believe, are obstructive and destructive participants in the company discussion and further development. Some for reasons that make little sense except in some false notion of "democracy". This is about avoiding liquidation and loss of one's shares by law, not democracy, and facilitating the continuing existence and development of the company and this opportunity. Then there are those who claim they are punitive or they need "more information", or whatever the latest claim is. I can't know their motivations, but I can evaluate the claims. Most are not reasonable at this stage in a company's lifecycle and make no sense.
Can't be done in the United States! That is my contention. It would be against the SEC Laws governing US Stocks.
If that were true you would be right but it wasn’t. A single source article, even one that relied only on the JAMA article without seeing if there were credentialed scientists who disagreed would be lazy journalism. The article in question did not cite Mr. Feuerstein alone.
Yes, a combination trial would be interesting, but their cost would make that very expensive in the long-run. But it would be interesting.
I think it’s more that anything that uses AF as the basis for the entirety of the article is going to be considered garbage.
They are as communicative as is reasonable given the circumstances, in my opinion. And they are not "blank checks", this is what they need to continue to operate and do the deals that shareholders would want at this life cycle stage. Anyone voting against allocation of shares must not want the company to continue, since a company at this stage can't continue forward at all, without the ability to pay its bills and it needs shares.
The basics of the law are that in a bankruptcy, shareholders LOSE their ownership pretty much entirely. If they are lucky, they might get a few pennies on the dollar in a reorg, but for a start-up company like this with no revenues, the assets will be sold dirt cheap and creditors get paid first.
So voting no is, as I have said, cutting off your nose to spite yourself if one is a shareholder. It makes absolutely no sense if one understands what is going on in the least bit.
I can see why shorts would argue for it. I can see why someone who needed the share price to drop so they could buy more before the vote affirms the request might argue to vote against. I mean, those are obvious things that happen with stocks like this frequently. Hedge funds and others manipulating and playing to miseducate retail. But for your average shareholder, such argumentation and behavior only has negative consequences.
Agreed. Reading the asm proxy is sad to me and has me expecting a complete beat down tomorrow.
only 4% of research papers gets accepted /published by JAMA !
Morten
@kaspersenInvest
$NWBO
1 in 400 trials with a revolutionary success . repeat … 1 ….. 400 !
only 4% of research papers gets accepted /published by JAMA !
This IS the golden needle in a haystack of manipulative, corrupt shorts. Haystack now soaked in petrol.
Horse, I've told this story before, but maybe it bears repeating. A friend of mine developed Glio. He did everything they asked him to, physical therapy, eating,chemo, helmet. He passed away about 13 months after diagnosis. I truly believe everything they told him to do did not add 1 day to his life. But I'm not a doctor.
My emotions say to vote against more shares. I'm a little angry the company hasn't provided more information on their plans. The flood of PR's. There are those that say the company couldn't be any clearer with their intentions, well, yes they can. But my head says to trust mngmt and to vote yes. I dont really have anywhere near enough shares to make the slightest bit of difference. Best comment I saw here all weekend was "next week should be interesting". I couldn't agree more. I'm interested to see what fireman has to say. Too much speculation right now. Everyone look at the bright side, in a few months tax refunds allow us to buy more shares. The results are spectacular. The world is finding out about dc-vax. the rest is just noise.
Any news article that is not in the tank for the NWBO is going to be considered a soft bash by hardcore supporters of the company.
Right now we’re lucky to get any third party coverage that is not either in the Feuerstein camp or the NWBO camp and if NWBO wants to better coverage or for the media to regurgitate the company line then they’d better quit firing PR firms right before they will be needed.
Sorry, ihub appears to be dropping parts of my, yours, and others posts so I didn’t get enough of the question to try an answer
From your lips to G-ds ears as they say back home. Other places in the neighborhood say ‘Inshallah’
Anyways I see Thermo has spoken so I’m a little more settled now ;).
Even $3 would be closer to $0.35 than $7.
They have been quietly getting the job done and anticipating the right developments in regulatory aspects, manufacturing at scale and economically, and holding out for the actual 5 year stats as opposed to projected estimates, among other things, while also raising funds along the way and dodging grenades.
I’m as frustrated as most in waiting with the sparsest shareholder communications ever, however I believe the smartest person in the room and her strong team are getting the job done and the proof is in the achievement!
It’s been a roller coaster ride for sure and not a fun one but every time I rack my brains against the available information and go through the logic, I come up with tremendous risk-reward and the risks are in decline lately!
They fail to mention that Warren Buffet makes money for his shareholders and extremely transparent and communicative.
For anyone to compare the two is beyond laughable
I agree the price is too high and should come down but currently there really are not any alternatives and they are approved and paid by most insurances so making hay while the sun shines. Perhaps if nwbo can get a marketing application actually submitted and approved then NVCR will have some competition.
Remember how the predictions for approval by now were common on this board but they have yet to even submit for approval(s). Seems EVERYTHING nwbo takes longer.
I may vote yes on increasing #shares but they first have to show they have a plan and a real timeline or I will just choose to not vote. Still hope they come thru and my guess of $7 by year end happens - not looking good so far.... Ou's guess of $0.35 seems a lot closer
Yes, Sir !! Kinda hard to imagine attaching a vaccine to a helmet OR maybe they will partner also using DCVax-L in combination with the TTF and extend survival in many patients ??? Hope so anyway!!!
Cheers,
BB
Poor Man -,
From a business perspective that seems to be a good way to look at this. I believe NWBO still wants to protect L/Direct combo research for certain potential situations where properly activated but reduced pace or more complete immune response is more desirable as synergy was noted in early DC research between intradermal and intratumoral injections by Triozzi et al. This may be taken care of by other combos but safety would likely not be an issue with this one. This synergy seems to point to a more complete local and systemic response. I expect their thinking about this to be clarified before being handed over Carte Blanche as progress with L is made. Best wishes.
It has to drop. Optune's pricing is insane. I get that they have to recoup the costs of trials. So I don't hold that against them. But I don't see how they remain competitive.
Meant to include the SPORE grant link to confirm the CSF-1Ri / PLX3397 trial with a PD-1 mAb blockade drug that could be BMY's drug given the previous trial that had been scheduled AND Dr. Liau's discussion of the CSF-1Ri related possible trial in her clinical discussion in the previous post, at the very bottom, previously highlighted by ATL.
Can happen under those circumstances.
i hope regulatory review doesn't take into account what is provided by shenanigan artists.
Followers
|
1633
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
720110
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |